John Childs Biography and Net Worth

Director of Biohaven

Mr. John W. Childs serves as the Chairman and Partner of J.W. Childs Associates, L.P., a private equity firm. He co-founded J.W. Childs Associates in 1995. Prior to founding J.W. Childs Associates, Mr. Childs was Senior Managing Director of the Thomas H. Lee Company from 1991 to 1995. In this capacity, he had broad responsibilities for originating, analyzing, negotiating and managing leveraged buyout transactions for the THL funds. For seventeen years prior to joining THL, Mr. Childs was with the Prudential Insurance Company of America where he held various executive positions in the investment area, ultimately serving as Senior Managing Director in charge of the Capital Markets Group. He is currently Chairman of Sunny Delight and a director of Kosta Browne, Esselte, Mattress Firm, WS Packaging and SIMCOM. Prior to its sale, he was Chairman of the Board of CHG Healthcare Services. Mr. Childs has a B.A. from Yale University and a M.B.A. from Columbia University.

What is John W. Childs' net worth?: The estimated net worth of John W. Childs is at least $43.08 million as of March 4th, 2025. Mr. Childs owns 2,320,571 shares of Biohaven stock worth more than $43,079,080 as of April 15th. This net worth approximation does not reflect any other investments that Mr. Childs may own. Learn More about John W. Childs' net worth.
How do I contact John W. Childs?: The corporate mailing address for Mr. Childs and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at jennifer.porcelli@biohavenpharma.com. Learn More on John W. Childs' contact information.
Has John W. Childs been buying or selling shares of Biohaven?: John W. Childs has not been actively trading shares of Biohaven during the last quarter. Most recently, on Tuesday, March 4th, John W. Childs bought 32,700 shares of Biohaven stock. The stock was acquired at an average cost of $30.47 per share, with a total value of $996,369.00. Following the completion of the transaction, the director now directly owns 2,320,571 shares of the company's stock, valued at $70,707,798.37. Learn More on John W. Childs' trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 10 times. They purchased a total of 368,886 shares worth more than $14,270,340.54. The most recent insider tranaction occured on March, 4th when Director John W Childs bought 32,700 shares worth more than $996,369.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 3/4/2025.

John W. Childs Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/4/2025	Buy	32,700	$30.47	$996,369.00	2,320,571
12/30/2024	Buy	29,000	$35.94	$1,042,260.00	2,368,741
10/2/2024	Buy	21,052	$47.50	$999,970.00	21,052
7/18/2024	Buy	28,400	$35.67	$1,013,028.00	2,339,741
5/30/2024	Buy	28,000	$35.58	$996,240.00	2,311,341
5/13/2024	Buy	28,500	$35.17	$1,002,345.00	2,283,341
8/30/2023	Buy	50,000	$18.44	$922,000.00	1,975,118
8/4/2023	Buy	100,000	$19.78	$1,978,000.00	1,925,118
11/10/2021	Buy	5,000	$122.87	$614,350.00
3/17/2021	Buy	13,157	$76.00	$999,932.00
3/2/2021	Buy	10,000	$85.14	$851,400.00	2,532,644
11/23/2020	Buy	5,000	$89.55	$447,750.00	2,516,938
9/21/2020	Buy	3,322	$59.25	$196,828.50	2,511,938
9/11/2020	Buy	6,678	$59.00	$394,002.00	2,508,616
4/6/2020	Sell	150,000	$31.25	$4,687,500.00	2,682,279
6/26/2019	Buy	10,000	$40.37	$403,700.00

John W. Childs Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $18.56

$17.98

$18.83

50 Day Range

MA: $30.03

$16.53

$42.67

2 Week Range

Now: $18.56

$15.79

$55.70

Volume

1,127,581 shs

Average Volume

1,127,227 shs

Market Capitalization

$1.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33